Gastrointestinal follicular lymphoma (GFL) is a rare type of non-Hodgkin lymphoma that primarily ... study that reported a high five-year overall survival rate of 100% for patients with duodenal ...

For slow-growing lymphomas, long-term survival ... growing follicular lymphoma The often more aggressive diffuse large B-cell lymphoma For decades, treatments for non-Hodgkin's lymphoma remained ...

The incidence of non-Hodgkin’s lymphoma (NHL) is increasing among ... characteristics and treatment approaches for both follicular and diffuse aggressive NHL histologies in elderly patients ...

A Phase I study included 13 patients with a variety of relapsed B-cell NHL (five follicular, three mantle cell, three DLBCL, two chronic lymphocytic leukemia/small-cell lymphoma [CLL/SLL]).

The five-year relative survival rate for stage 4 Hodgkin lymphoma is 81 percent, and 64 percent for stage 4 non-Hodgkin lymphoma. Everyday Health follows strict sourcing guidelines to ensure the ...

The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients with relapsed/refractory follicular lymphoma Compared to placebo, the ...

The marginal zone lymphoma trial is unique in that most clinical trials don't separate out patients with this type of cancer because it is relatively rare, comprising only 6 to 8% of non-Hodgkin ...

Follicular lymphoma is the second most common form of non-Hodgkin lymphoma (NHL), and is ... and it has a five-year survival rate of only 20% for patients in the third line and later.

Roche has secured its first regulatory approval for mosunetuzumab, a first-in-class CD20xCD3 bispecific antibody, as a treatment for patients with follicular ... form of non-Hodgkin lymphoma ...

Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy where patients' T-cells are collected and genetically modified to produce chimeric antigen receptors that recognize ...